Cargando…

Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital....

Descripción completa

Detalles Bibliográficos
Autores principales:	Seppälä, Elina, Veneti, Lamprini, Starrfelt, Jostein, Danielsen, Anders Skyrud, Bragstad, Karoline, Hungnes, Olav, Taxt, Arne Michael, Watle, Sara Viksmoen, Meijerink, Hinta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2021
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414959/ https://www.ncbi.nlm.nih.gov/pubmed/34477054 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.35.2100793

Ejemplares similares

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2023)

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020–June 2021
por: Starrfelt, Jostein, et al.
Publicado: (2022)

Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 – January 2022
por: Langlete, Petter, et al.
Publicado: (2023)

No difference in risk of hospitalization between reported cases of the SARS-CoV-2 Delta variant and Alpha variant in Norway
por: Veneti, Lamprini, et al.
Publicado: (2022)

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
por: Veneti, Lamprini, et al.
Publicado: (2022)

Minimal transmission of SARS-CoV-2 from paediatric COVID-19 cases in primary schools, Norway, August to November 2020
por: Brandal, Lin T, et al.
Publicado: (2021)

Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
por: Brandal, Lin T., et al.
Publicado: (2021)

Comprehensive Contact Tracing, Testing and Sequencing Show Limited Transmission of SARS-CoV-2 between Children in Schools in Norway, August 2020 to May 2021
por: Winje, Brita Askeland, et al.
Publicado: (2021)

Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 –May 2021
por: Veneti, Lamprini, et al.
Publicado: (2021)

Trajectories of hospitalisation for patients infected with SARS-CoV-2 variant B.1.1.7 in Norway, December 2020 – April 2021
por: Whittaker, Robert, et al.
Publicado: (2021)

Genetic emergence of B.1.617.2 in COVID-19
por: Kirola, L.
Publicado: (2021)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients
por: Whittaker, Robert, et al.
Publicado: (2022)

Molecular Epidemiology of the Norwegian SARS-CoV-2 Delta Lineage AY.63
por: Moen, Line Victoria, et al.
Publicado: (2022)

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
por: Vikse, Elisabeth Lea, et al.
Publicado: (2023)

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Vaccine effectiveness against the B.1.617.2 in the intensive care unit
por: Koc, Ibrahim, et al.
Publicado: (2023)

Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — Mesa County, Colorado, April–June 2021
por: Herlihy, Rachel, et al.
Publicado: (2021)

Genome Sequences of the Delta Variant (B.1.617.2) and the Kappa Variant (B.1.617.1) Detected in Morocco
por: Melloul, Marouane, et al.
Publicado: (2021)

Genome Sequence of an Early Imported Case of SARS-CoV-2 Delta Variant (B.1.617.2 AY.122) in Iraq in April 2021
por: Al-Rashedi, Nihad A. M., et al.
Publicado: (2022)

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant
por: Cai, Changjing, et al.
Publicado: (2021)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
por: Lopez Bernal, Jamie, et al.
Publicado: (2021)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)

SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021
por: Dougherty, Kendra, et al.
Publicado: (2021)

Community spread and late season increased incidence of oseltamivir‐resistant influenza A(H1N1) viruses in Norway 2016
por: Bragstad, Karoline, et al.
Publicado: (2019)

Outbreak of SARS-CoV-2 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison — Texas, July–August 2021
por: Hagan, Liesl M., et al.
Publicado: (2021)

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Serial intervals in SARS-CoV-2 B.1.617.2 variant cases
por: Pung, Rachael, et al.
Publicado: (2021)

Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
por: Arora, Prerna, et al.
Publicado: (2021)

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
por: Prandi, Ingrid Guarnetti, et al.
Publicado: (2022)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
por: Mlcochova, Petra, et al.
Publicado: (2021)

Chest CT features of children infected by B.1.617.2 (Delta) variant of COVID-19
por: Cheng, Qi-Rui, et al.
Publicado: (2021)

Codon usage divergence in Delta variants (B.1.617.2) of SARS-CoV-2
por: Li, Gun, et al.
Publicado: (2022)

Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Chun, June Young, et al.
Publicado: (2022)

Charge transport properties of SARS-CoV-2 Delta variant (B.1.617.2)
por: He, Lijun, et al.
Publicado: (2022)

Enhanced fitness of SARS-CoV-2 B.1.617.2 Delta variant in ferrets
por: Sun, Xiangjie, et al.
Publicado: (2023)

COVID-19 among immigrants in Norway, notified infections, related hospitalizations and associated mortality: A register-based study
por: Indseth, Thor, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_duep7i4oa345h1gv63c14n8d53